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The virB locus, which encodes the type IV secretion system, is a major component of viru-
lence in Brucella. A non-polar virB10mutant and a virB11 deletionmutant were constructed
in Brucella canis. In the mouse model, both mutants were cleared at day 21 post-infection,
indicating reduced virulence in mice. After challenging with wild-type B. canis, the amounts
of CFU recovered at day 15 were signiﬁcantly lower in the group previously vaccinated with
the virB10 mutant. Levels of IgG1, IgG2a, IgG2b, and IgM, the induction of the cytokines IL-
2, IL-4, IL-10, and the production of IFN-γ were measured in lymphocyte cultures. All strains
elicited similar levels of different antibody isotype proﬁles, and no signiﬁcant differences
were detected (P < 0.05).The wild-type strain induced a rapid and strong INF-γ response at
24 h, while both mutants induced mild INF-γ responses at 24 h, which remained constant
over the course of sampling. Our results suggest that the virB mutants elicit a protective
immunity andmay be considered as candidates for studies to be conducted in dogs against
canine brucellosis.
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INTRODUCTION
The Brucella genus consists of Gram-negative, facultative intracel-
lular microorganisms that cause disease in diverse animal species,
including humans (Sieira et al., 2000). Brucella species can sur-
vive within professional and non-professional phagocytes, thus
avoiding the host defense mechanisms. Host resistance to facul-
tative intracellular pathogens such as Brucella depends mainly on
the induction of cell-mediated immunity (Golding et al., 2001;
Baldwin and Parent, 2002; Baldwin andGoenka, 2006). The capac-
ity of antigens to selectively induce a Th1 or Th2 response is an
important aspect in the development of vaccines against intracel-
lular Brucella pathogens (Zhan et al., 1996). Studies performed
in the murine model show that live attenuated vaccines induce a
cellular response characterized by the production of IFN-γ and
IL-2 (Zhan et al., 1995). In the case of canine brucellosis, no vac-
cine is available; thus, studies concerning Brucella canis virulence
factors, as well as interactions between host–pathogen should be
performed in order to develop immunogens to prevent disease
in dogs.
A virulence factor that has been shown to be essential for Bru-
cella is the type IV secretion system (T4SS), which is encoded
by the virB operon (Hong et al., 2000; Sieira et al., 2000) and
is required for the establishment and persistence of infection in
the murine model (Sun et al., 2002; Rolan and Tsolis, 2008). It
has been shown that virB mutants of B. abortus and B. meliten-
sis have reduced capacities to survive and replicate in professional
and non-professional phagocytic cells (Sun et al., 2005; Rolan and
Tsolis, 2008).
In this study, a B. canis non-polar virB10 mutant and a virB11
null mutant were evaluated for their roles in protecting against
an experimental challenge. The induction of the cytokines IL-2,
IL-4, and IL-10 as well as the production of IFN-γ in spleen cells
from mice inoculated with B. canis mutants were assessed, as was
the production of IgG1, IgG2a, IgG2b, and IgM in the murine
model.
MATERIALS AND METHODS
BACTERIA STRAINS, MEDIA, AND CULTURE CONDITIONS
The B. canis wild-type strain, the mutants virB10 and virB11, and
their complemented mutants were cultured at 37˚C in Brucella
agar or Brucella broth with orbital shaking (200 rpm) for 18 h.
Escherichia coli JM109 and DH5α strains were cultured at 37˚C
in Luria–Bertani agar or broth with orbital shaking (200 rpm) for
18 h. When necessary, the following antibiotics were added: gen-
tamycin (2.5μg/ml) and ampicillin (50 μg/ml; SIGMA Aldrich,
St. Louis, MO, USA).
CONSTRUCTION OF virB10 AND virB11 MUTANTS
To obtain a non-polar mutation in the virB10 gene, an insertional
mutant was constructed. The plasmid pB2A3, which contains the
virB10 gene, was linearized with NruI and ligated with a 0.7-kb
SmaI fragment encoding a gentamycin resistance cassette. The
resulting plasmid, pB2A3::Gm, was electroporated into B. canis
where it is incapable of autonomous replication, and double-
homologous recombinant events (Gmr Amps) were selected using
gentamicin resistance (Sieira et al., 2000).
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To generate a mutant with a deletion in the virB11 gene, a
1.2-kb fragment of the plasmid pGEM-T-virB10 that contained
a virB10 gene was ligated into pBluescript KSII to generate the
plasmid pBlue-virB10. A 0.7-kb BamHI fragment encoding a
gentamycin resistance cassette was ligated into the BamHI site
of pBlue-virB10 to generate the plasmid pBlue-virB10-Gm. An
850-bp that contained the orf13-orf12 region was cloned into
the pGEM-T Easy vector and was recovered by Not I digestion.
This fragment was ligated into pBlue-virB10 at the Not I site
to generate the plasmid pBlue-virB10::Gm-ORF13-ORF12. Five
micrograms of pBlue-virB10::Gm-ORF13-ORF12 was electropo-
rated into wild-type B. canis. Accordingly, colonies that were
Gmr and Amps were selected as possible double-homologous
recombinants.
COMPLEMENTATION OF BRUCELLA CANIS virB10 AND virB11
NON-POLAR MUTANTS
The entire virB10 gene was cloned into the pBBR1MCS-4 plasmid
at theEcoRI site to generate the pGP10c plasmid. The pGP10c plas-
midwas electroporated into B. canis virB10::Gm,andAmpr strains
were selected. The presence of the plasmid was conﬁrmed by alka-
line lysis. To restore the virB11 gene, the complete gene was intro-
duced into the pBBR1MCS-4 plasmid at the EcoRI site to generate
the pGP11c plasmid. The pGP11c plasmid was then transformed
into B. canis ΔvirB11::Gm by electroporation; Ampr strains were
selected, and the presence of the plasmidwas conﬁrmedby alkaline
lysis.
EXPERIMENTAL INFECTION IN MICE
Female 6- to 7-week-old BALB/c mice were obtained from Har-
lan, Mexico. The mice were placed in cages with water and feed
ad libitum and were acclimated for 1week before beginning the
experiments. Three groups of 16 mice each were formed for the
in vivo virB mutant protection experiments.
SURVIVAL OF virB MUTANTS IN MICE
The survival of virB mutants, of the complemented mutants
virB10::Gm and ΔvirB11::Gm and of wild-type B. canis was deter-
mined by quantitating the CFU of each strain in mouse spleens
at different time intervals post-infection. Groups of 15 7-week-
old female BALB/c mice were injected i.p. with 1.4× 108 CFU
of the virB10::Gm strain or the ΔvirB11::Gm strain in 0.1ml
of PBS. At 7, 21, 35, and 45 days post-infection (p.i.), animals
were sacriﬁced, and spleens were removed and homogenized in
PBS. Tissue homogenates were serially diluted with PBS and were
plated onto tryptic soy broth-agar with the appropriate antibiotics
to determine the numbers of CFU per spleen.
For protection experiments, groups of 16 mice were immu-
nized i.p. with 1.4× 108 CFU of strain virB10::Gm or strain
ΔvirB11::Gm or with PBS (unvaccinated control). Six weeks post-
inoculation, both groups were challenged i.p. with 5× 104 CFU
of virulent wild-type B. canis per mouse. Two and 4weeks post-
challenge, eight mice per group were sacriﬁced, and the numbers
of CFU recovered from spleens were determined. Protection units
were deﬁned as the difference between the mean log of the num-
bers of CFU from immunized mice and that of the numbers of
CFU from mice receiving saline.
LYMPHOCYTE CULTURES AND CYTOKINE INDUCTION
Three groups of ﬁve 6- to 7-week-old female BALB/c mice were
immunized intraperitoneally with 1.4 × 108 CFU/ml of B. canis
or the virB mutants; each mouse was inoculated at both day 0
and 8. Fifteen days after the ﬁrst inoculation, the mice were sacri-
ﬁced, and spleens were extracted for lymphocyte cultures. Spleens
from each group of mice were combined and washed three times
with Hank’s balanced salt solution and were placed in a Petri dish
that contained 5ml of RPMI 1640 medium (Gibco, Laboratories)
supplemented with 100U/ml of penicillin and 100μg/ml of strep-
tomycin. The spleens were wrapped with sterile gauze to retain
tissue portions and were then macerated. The cellular suspension
was transferred into a tube with 5ml of the same medium and
was centrifuged at 400× g for 3min. The cells were re-suspended
in 0.17M ammonium chloride for 5min at 4˚C to lyse erythro-
cytes, and they were then washed three additional times with
RPMI. Cells were re-suspended in RPMI medium enriched with
20% bovine fetal serum, 200mM l-glutamine and 0.1mM non-
essential amino acids. A total of 6.5× 106 mouse lymphocytes
were stimulated with their corresponding mutant or the wild-type
strain and were then each distributed into ﬁve wells in cell cul-
ture plates (Nunclon, Rochester, NY, USA). Wells were inoculated
with 108 CFU of each one of the strains, and the plates were then
incubated at 37˚C with 5% CO2. A positive control was inoculated
with concanavalin A. Supernatants were collected at 24, 48, 72, 96,
and 120 h after inoculation and were frozen until use; commercial
kits were used for the quantiﬁcation of mouse cytokines IFN-γ,
IL-2, IL-4, and IL-10 (Duoset ELISA; R&D Systems, Minneapolis,
MN, USA) following the manufacturer’s instructions.
DETECTION OF SPECIFIC ANTIBODIES IN SERUM
Antibodies against virB mutants were quantiﬁed by indirect
ELISA using a total extract of wild-type B. canis as the antigen.
Three groups of 15 mice were immunized intraperitoneally with
1.4× 108 CFU/ml of wild-type B. canis and its mutants, and sera
were obtained at 0, 7, 14, 21, and 28 days post-inoculation. IgG1,
IgG2a, IgG2b, and IgM isotypes were evaluated using a commer-
cial mouse monoclonal antibody isotyping reagent kit (Sigma
Aldrich,St. Louis,MO,USA) following themanufacturer’s instruc-
tions. Plates were read at a wavelength of 490 nm (VICTOR ELISA
reader).
STATISTICAL ANALYSIS
Signiﬁcance levels were determined using Student’s t -test to com-
pare between vaccinated and unvaccinated groups and among
days. A value of P < 0.05 was considered signiﬁcant.
RESULTS
CHARACTERIZATION AND COMPLEMENTATION OF B. CANIS
virB10::Gm AND B. CANIS ΔvirB11::Gm MUTANTS
A total of 5μg of pB2A3::Gm plasmid was electroporated with
a GenePulser (Bio-Rad) into B. canis wild-type strain; colonies
displaying Gmr and Amps were selected to obtain mutants with
a homologous double recombination (GmrAms). PCR analy-
sis conﬁrmed that the wild-type virB10 gene was replaced. The
mutated region was ampliﬁed to determine the interruption of
the virB10 gene using primers that amplify a 1369-bp fragment
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for the parental strain and a 2069-bp fragment for the mutant
strain. This procedure generated the non-polar mutant, B. canis
virB10::Gm.
The plasmid pBlue-virB10::Gm-ORF13-ORF12 was electropo-
rated with a GenePulser (Bio-Rad) into B. canis wild-type strain to
generate the deletion of the virB11 gene. Gmr and Amps colonies
were selected and then analyzed by PCR to conﬁrm that the
replacement of virB11 with Gm had occurred. This procedure
generated the non-polar B. canis mutant, ΔvirB11::Gm. To con-
ﬁrm the interruption of the virB11 gene, an ampliﬁcation of the
mutated region was performed using primers that amplify a 2013-
bp fragment for the wild-type strain and a 1900-bp fragment
for the mutant strain. This procedure generated the non-polar
mutant, B. canis ΔvirB11::Gm.
To restore the virB10 gene, a 1.2-kb fragment containing the
entire virB10 gene was ampliﬁed and cloned directly into pCR2.1
TOPO; the resulting plasmidwas namedpGP10c. Plasmid pGP10c
was digested with EcoRI to recover a 1.2-kb fragment, which was
ligated into pBBRMCS-4-EcoRI to generate a pBBR4-virB10. This
plasmid was electroporated into B. canis virB10::Gm, and strains
resistant to ampicillin were selected. The presence of the plasmid
was conﬁrmed using alkaline lysis.
To restore the virB11 gene, the complete gene was ampliﬁed
and cloned directly into pCR2.1 TOPO; the resulting plasmid was
named pGP11c. This plasmid was digested with EcoRI to gener-
ate a 1.3-kb product that contained the entire virB11 gene. The
1.3-kb fragment was ligated into the pBBR1MCS-4 plasmid at the
EcoRI site to generate the pBBR4-virB11 plasmid. This plasmid
was transformed into B. canis ΔvirB11::Gm by electroporation,
ampicillin-resistant strains were selected and the presence of the
plasmid was conﬁrmed by alkaline lysis.
EXPERIMENTAL INFECTION IN MICE
To evaluate the survival of the virB10 and virB11 mutants,
the complemented mutants virB10::Gm and ΔvirB11::Gm and
B. canis wild-type strain in vivo, groups of mice were inoc-
ulated intraperitoneally with 1.4 × 108 CFU of the strains in
0.5ml of PBS; at different times, the numbers of CFU/ml were
determined from spleens. Experimental results revealed that at
7 days post-infection, there were no differences in the recov-
ered CFU of the different strains. By the third week, mutant
virB10 had already been completely eliminated, thus indicating
a notable reduction in virulence. Compared to the wild-type
strain, mutant virB11 reduced its bacterial load by 0.2 logs by
week 3, and at week 5, the levels were undetectable, suggest-
ing that the loss of some of the virB genes resulted in the
elimination of the bacteria from the mouse spleens. Mutant
virB11 complemented with plasmid pBBR4-virB11 recovered
its virulence and replicated similarly to the wild-type strain
(Figure 1).
To examine the protection induced by virB mutants, an
immunization experiment was performed. Mice were inocu-
lated i.p. with 1.4× 108 CFU of virB10::Gm, ΔvirB11::Gm, or
with PBS. Six weeks post-inoculation, animals were challenged
with 5× 104 CFU of B. canis wild-type strain. Protection was
deﬁned as the difference between the numbers of viable bacteria
recovered from spleens of immunized mice and those recovered
FIGURE 1 |Virulence in mice. Mice were infected i.p. with 1.4×108 CFU
of B. canis wild-type strain, the virB10 and virB11 mutants or the
virB-complemented mutant strains, and the numbers of CFU recovered
from spleens at different times post-infection were determined as
described in the Section “Materials and Methods”.  B. canis
ΔvirB11::Gmr; • B. canis virB11::Gmc;  B. canis virB10::Gmr; ∗ B. canis
virB10::Gmc;  B. canis wild type.
Table 1 | Protection against B. canis wild-type.
Treatment group
(n =8)
receiving
Mean log10 of the no. of
brucellae±SD in spleens on
post-challenge day
Log10 of
protectiona
on day
15 30 15 30
virB10::Gm 3.84±0.58 3±0.47 1.72b 1.91b
ΔvirB11::Gm 4.8±0.68 2.95±0.46 0.76 1.96b
PBS 5.56±0.74 4.91±0.69
aLog10 of protection is deﬁned as the difference between themean log of the num-
bers of CFU from immunized mice and that of the numbers of CFU from mice
receiving saline. bP<0.05 (signiﬁcant) compared with value for control mice.
from spleens of mice that received saline; results are summa-
rized in Table 1. The virB10::Gm inoculation generated signiﬁcant
protection 15 and 30 days post-challenge (1.72 and 2 protection
units, respectively). As expected, ΔvirB11::Gm also induced sig-
niﬁcant protection at day 30 (1.96 protection units). These results
emphasize the potential of this mutant for use as a live vaccine
for dogs.
MUTANTS INDUCE A HUMORAL RESPONSE SIMILAR TO WILD-TYPE
INFECTION
Sera collected at 0, 7, 14, 21, and 28 days post-vaccination were
used to detect the presence of speciﬁc antibodies against B. canis by
ELISA. Immunization with virB mutants stimulated an antibody
response with IgG1, IgG2a, IgG2b, and IgM isotypes. A similar
distribution occurred in the sera of mice inoculated with the wild-
type strain.Although IgG2a levels increase inmice vaccinatedwith
virB10, on day 21 post-infection, there are no signiﬁcant differ-
ences (P < 0.05) compared to the sera of mice challenged with the
wild-type strain, in which IgG2a levels increase up to day 28 (data
not shown).
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CYTOKINE RESPONSES BY virB MUTANTS
The immune cellular response was characterized based on the
secretion of cytokines at different times in supernatants of lym-
phocyte cultures obtained from mice previously immunized and
later stimulated with the corresponding strains. The wild-type
strain induces a rapid and strong INF-γ response with a marked
reduction at 96 h, while IL-10 is slightly increased at 72 h. There
was no signiﬁcant difference (P > 0.05) in the production of INF-
γ between virB10 and virB11 mutants. IL-2 and IL-4 levels for
both mutants were not statistically signiﬁcant compared to those
produced by the spleen cells of mice inoculated with the wild-type
strain (Figure 2).
DISCUSSION
The development of a live vaccine for the control and eradica-
tion of canine brucellosis is of great importance. Nevertheless,
currently, there is no information that describes an appropriate
candidate that can be used as a vaccine against B. canis.
In this study, itwas shown that virB10 and virB11 genes perform
an essential role in B. canis virulence in mice. Studies published
by other groups conﬁrm these results and also show that these
genes fulﬁll the same function in other Brucella species (Hong
et al., 2000; Sieira et al., 2000; Comerci et al., 2001; Delrue et al.,
2001; Boschiroli et al., 2002; Celli et al., 2003). Through the con-
struction of mutants, it has been shown that the alteration of
either virB10 or virB11 with non-polar mutations has a detri-
mental effect on virulence. Comerci et al. (2001) used non-polar
mutations to demonstrate that virB4, virB8, and virB10 genes are
required for the persistence of Brucella infection, while Den Har-
tigh et al. (2008) demonstrated that non-polarmutations in virB10
and virB11 are essential for B. abortus virulence in mice.
Brucella virulence mechanisms are not fully understood, but
the capacity to cause disease is related to the intracellular survival
of the bacteria, which has been associated with the T4SS (Hong
et al., 2000; Comerci et al., 2001; Delrue et al., 2001; Boschiroli
et al., 2002; Celli et al., 2003). In this study, we conclude that
the absence of B. canis virB10 and virB11 genes from the virB
operon is associated with a reduction of virulence in mice. Sieira
et al. (2000) demonstrated that a B. abortus virB10 mutant could
not be recovered from the spleens of infected mice. In this study,
non-polar virB mutants had reduced spleen counts compared to
the wild-type strain, indicating severe reductions in virulence as
estimated by the numbers of viable bacteria from the spleens at
all times p.i that were assessed. This phenotype is likely due to a
faulty secretion of effector molecules as a result of a T4SS that
works deﬁciently in the absence of some virB gene. We also ana-
lyzed the protection properties of virB mutants in the BALB/c
mouse model. Our results show that the mutants protect mice
from a challenge with a virulent strain of wild-type B. canis with
a reduction of approximately 2 log units.
FIGURE 2 | Production of cytokines in stimulated spleen cells from
BALB/c mice vaccinated with virB mutants. Mice were vaccinated with
108 CFU of either the virB10 mutant or the virB11 mutant. The control group
received PBS. At 15 days post-vaccination, mice were euthanized, and
splenocytes were harvested and stimulated with heat-inactivated B. canis
wild-type strain or concanavalin A as a positive control. Supernatants were
harvested at 24, 48, 72, 96, and 120 h and were then assayed for IFN-γ (A),
IL-2 (B), IL-4 (C), and IL-10 (D) production (pg/ml) at different times of
stimulation using a multiplex suspension array system (Sigma Aldrich, St.
Louis, MO, USA).
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Even though there are detectable levels of anti-Brucella IgG,
the antibody response to immunization was considered to be
low compared to other virulence factors used in immunizations;
nevertheless, the IgG1 and IgG2a levels were heterogeneous in
both mutants. Our results and numerous examples in the lit-
erature indicate that INF-γ levels produced in response to a
vaccination candidate do not always correlate with the efﬁcacy
of the vaccine during a challenge with Brucella. Various in vitro
studies have demonstrated that murine spleen cells previously
inoculated with live vaccines induce a type Th1 response to Bru-
cella antigens, while those immunized with inactivated vaccines
induce a type Th2 response (Zhan et al., 1995). In mice infected
with B. abortus virB mutants, serum levels of immunoglob-
ulin IgG2a and cytokines INF-γ and IL-12p40 increase more
than in mice infected with B. abortus wild-type strain (Rolan
and Tsolis, 2008). Our results suggest that the virB mutants
elicit a strong protective immunity and should be considered
as candidates for live vaccines for dogs. The evaluation of the
mutants generated by insertion of the gentamycin resistance cas-
sette as a selection marker is permitted in our country (Mexico);
however, to be considered as a candidate for a live vaccine, it
will be necessary to reconstruct the mutants and remove the
gentamycin selection marker using counterselectable sacB as a
selection marker.
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